NEWS RELEASE FROM CARDIODIGITAL

Blood Pressure Technology Purchase Strengthens Scottish Medical Device Company's Portfolio

Anaesthetists in the operating theatre have long recognized the desirability of continuous blood pressure monitoring but the 'gold-standard,' an invasive arterial line, is costly, invasive, and has some degree of risk. Continuous non-invasive measurement of blood pressure represents one of the 'Holy Grails' of monitoring.

CardioDigital Ltd announced today that it has successfully acquired a technology portfolio relating to continuous non-invasive blood pressure (CNIBP) measurement from Canadian firm VSM MedTech of Vancouver, British Columbia.

The opportunity to purchase the technology came as a result of VSM's restructuring programme as it focuses on its brain imaging (MEG) technology.

Professor Paul Addison, co-founder and Chief Executive Officer of CardioDigital, stated that:

"The acquisition of CNIBP adds strength and depth to CardioDigital's technology portfolio. CNIBP dovetails with the company's existing pulse oximetry technologies, as both employ the same clinical probe. Pulse oximetry is already a major area of strength of the company, which has developed a range of proprietary technologies for this ubiquitous clinical device."

The CNIBP system overcomes practical limitations of currently available systems and meets the demanding needs of healthcare practitioners. The technology benefits patients and healthcare providers by allowing earlier blood pressure trend detection, thereby allowing for prompt treatment. Other recently introduced methods for measurement of continuous non-invasive blood pressure use unfamiliar methods, are vulnerable to motion artifact, and are difficult to use.

Prototype systems, which came as part of the deal, have already been tested in a series of clinical trials, meeting regulatory guidelines for blood pressure accuracy. The CNIBP system, optimised by CardioDigital, will offer a cost-effective advancement in monitoring, meeting long-recognized patient care needs in surgical and other acute care environments.

Professor Addison added:

"The acquisition places CardioDigital in a particularly strong position in the marketplace with a range of closely linked technologies applicable to general ward use, the operating theatre, critical care, at-risk neonatal care and home sleep diagnostics. CNIBP will widen the product opportunity available to CardioDigital, enhancing its ability to address high growth, global markets in pulse oximetry-based device sectors. "


Ends

For more details please contact:

Prof Professor Paul S Addison
CEO
CardioDigital Ltd
Elvingston Science Centre
East Lothian
EH33 1EH
United Kingdom
T. +44 (0)1875 408 175
M: +44 7913 110 4871
F. +44 (0)1875 408 001
Mike Findlay - Wellcome Trust Media Officer
T +44 (0)20 7611 8612
E m.findlay@wellcome.ac.uk

 

EDITORS NOTES

Blood Pressure Monitoring
There is substantial evidence that (1) decreasing the duration and extent of blood pressure fluctuations in the operating theatre decreases morbidity and (2) current 3-5 minute automated blood pressure readings often fail to detect significant fluctuations or detect them only after significant delay.

The CNIBP technology will be developed by CardioDigital to continuously, non-invasively, and accurately monitor blood pressure using methods already familiar to virtually all clinical practitioners. The solution requires a double pulse oximeter probe, an optimized adhesive sensor, and a conventional blood pressure cuff.

The CNIBP system overcomes practical limitations of currently available systems and meets the demanding needs of healthcare practitioners. The technology benefits patients and healthcare providers by allowing earlier blood pressure trend detection, thereby allowing for prompt treatment. Other recently introduced methods for measurement of continuous non-invasive blood pressure use unfamiliar methods, are vulnerable to motion artifact, and are difficult to use. The prototype systems have already been clinically tested in over 300 surgical patients, meeting regulatory guidelines for blood pressure accuracy. The optimized CNIBP system will offer a cost-effective advancement in monitoring, meeting long-recognized patient care needs in surgical and other acute care environments.

CardioDigital Ltd
The company was established in 2001 with the vision of becoming a world leading supplier of unique signal analysis solutions. CardioDigital specialises in novel medical signal analysis solutions for medical devices. The company's main focus is on two market sectors: defibrillator and pulse oximeter products. The company spun out from Napier University, Edinburgh and is currently based at Elvingston Science Centre in East Lothian, just outside the city. The company's main investor is the Wellcome Trust, the UK's largest medical charity.

The medical device sector is particularly receptive to technology pull and there is a strong precedent for new technologies to generate increased market share. Through its proprietary signal processing techniques aligned with strong, well protected IP, CardioDigital is well placed to be in the vanguard of 21st century patient monitoring with enhanced device utility stimulating increased sales for our target customer base.